The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Taysha Gene Therapies Inc shares valued at $1,172,812 were sold by Nagendran Sukumar on Dec 01 ’25. At $4.51 per share, Nagendran Sukumar sold 260,047 shares. The insider’s holdings dropped to 1,006,439 shares worth approximately $5.49 million following the completion of this transaction.
Also, Nagendran Sukumar sold 110,125 shares, netting a total of over 523,094 in proceeds. Following the sale of shares at $4.75 each, the insider now holds 1,006,439 shares.
Before that, Nagendran Sukumar had added 370,172 shares to its account. In a trade valued at $1,799,036, the Officer bought Taysha Gene Therapies Inc shares for $4.86 each.
As published in their initiating research note from Raymond James on October 21, 2025, Taysha Gene Therapies Inc [TSHA] has been a Strong buy and the price target has been revised to $13. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in mid July. As of June 27, 2024, BMO Capital Markets has initiated its “an Outperform” rating for TSHA. Earlier on April 09, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for TSHA stock.
Analyzing TSHA Stock Performance
On last trading session, Taysha Gene Therapies Inc [NASDAQ: TSHA] rose 0.18% to $5.45. The stock’s lowest price that day was $5.37, but it reached a high of $5.72 in the same session. During the last five days, there has been a drop of approximately -5.38%. Over the course of the year, Taysha Gene Therapies Inc shares have jumped approximately 171.14%. Shares of the company reached a 52-week high of $5.95 on 12/15/25 and a 52-week low of $1.05 on 04/09/25.
Support And Resistance Levels for Taysha Gene Therapies Inc (TSHA)
According to the 24-hour chart, there is a support level at 5.31, which, if violated, would cause prices to drop to 5.16. In the upper region, resistance lies at 5.66. The next price resistance is at 5.86. RSI (Relative Strength Index) is 59.06 on the 14-day chart, showing neutral technical sentiment.
Is Taysha Gene Therapies Inc subject to short interest?
Stocks of Taysha Gene Therapies Inc saw a sharp rise in short interest on 2025-11-28 jumping by 4.67 million shares to 49.04 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 44.37 million shares. A jump of 9.51% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 13.26 of the overall float, the days-to-cover ratio (short ratio) jumped to 13.26.
Which companies own the most shares of Taysha Gene Therapies Inc (TSHA)?
In terms of Taysha Gene Therapies Inc share price expectations, FactSet research, analysts set an average price target of 11 in the next 12 months, up nearly 102.21% from the previous closing price of $5.44. Analysts anticipate Taysha Gene Therapies Inc stock to reach 13 by 2025, with the lowest price target being 8. In spite of this, 8 analysts ranked Taysha Gene Therapies Inc stock as Buy at the end of 2025. On February 01, 2023, Jefferies assigned a price target of “a Hold” to the stock and downgraded coverage with a $1.50.
